Evidence map›Paper›PMID 39597090›Full record

ArticleMedicina (Kaunas, Lithuania)2024

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM).

Josip Batinić, Barbara Dreta, Goran Rinčić, Antonia Mrdeža, Karla Mišura Jakobac, Delfa Radić Krišto, Milan Vujčić, Mario Piršić, Željko Jonjić, Vlatka Periša and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Josip BatinićDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Barbara DretaDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Goran RinčićDivision of Hematology, Sisters of Charity Hospital, 10000 Zagreb, Croatia.
Antonia MrdežaDivision of Hematology, Sisters of Charity Hospital, 10000 Zagreb, Croatia.ORCID 0000-0003-2960-5444
Karla Mišura JakobacDivision of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia.ORCID 0000-0001-7353-8811
Delfa Radić KrištoSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Milan VujčićDivision of Hematology, University Hospital Split, 21000 Split, Croatia.ORCID 0000-0002-9848-2225
Mario PiršićDivision of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia.
Željko JonjićDivision of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia.
Vlatka PerišaDivision of Hematology, University Hospital Centre Osijek, 31000 Osijek, Croatia.
Jasminka Sinčić PetričevićDivision of Hematology, University Hospital Centre Osijek, 31000 Osijek, Croatia.
Božena CohaDepartment of Internal Medicine, General Hospital "Dr. Josip Benčević", 35000 Slavonski Brod, Croatia.
Hrvoje HolikDepartment of Internal Medicine, General Hospital "Dr. Josip Benčević", 35000 Slavonski Brod, Croatia.
Toni ValkovićDepartment of Internal Medicine, Specialty Hospital Medico, 51000 Rijeka, Croatia.
Marija StanićDivision of Hematology, Department of Internal Medicine, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia.
Ivan KrečakDepartment of Internal Medicine, General Hospital Šibenik, 22000 Šibenik, Croatia.ORCID 0000-0002-8642-305X
Ante StojanovićSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0009-0009-9310-4426
Domagoj SajfertSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0009-0000-6367-1264
Sandra Bašić-KindaDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Boron CompoundsDexamethasoneGlycineMultiple MyelomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCroatiaFemaleHumansKaplan-Meier EstimateLenalidomideMaleMiddle AgedAntineoplastic AgentsBoron CompoundsDexamethasoneGlycineixazomibLenalidomideixazomiblenalidomidemultiple myelomarelapsed/refractoryretrospective study

Identifiers

PMID39597090
PMCPMC11596887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.